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Distinct mesenchymal progenitor cell subsets in the adult
human synovium
Alexandra Karystinou1, Francesco Dell’Accio2, Tobias B. A. Kurth1, Henning Wackerhage1,
Ilyas M. Khan3, Charles W. Archer3, Elena A. Jones4, Thimios A. Mitsiadis5 and Cosimo De Bari1
Objective. To analyse the heterogeneity at the single-cell level of human mesenchymal progenitor cells from SM.
Methods. Cell populations were enzymatically released from the knee joint synovium of adult human individuals. Single cell-derived clonal
populations were obtained by limiting dilution and serially passaged to determine growth rates. Phenotypic analysis was carried out by flow
cytometry. Replicative senescence was assessed by the senescence-associated -galactosidase staining. Telomere lengths were
determined semiquantitatively by Southern blotting. Telomerase activity was measured using a real-time quantitative telomerase repeat
amplification procedure. Culture-expanded clonal populations were subjected to in vitro differentiation assays to investigate their mesen-
chymal multipotency.
Results. The 50 clones analysed displayed wide variations in the proliferation rates, even within the same donor sample. The time taken to
reach 20 population doublings ranged from 44 to 130 days. The phenotype of the clones tested was compatible with that of mesenchymal
stem cells. Mean telomere lengths ranged from 5.2 to 10.9 kb with positive linear trend with telomerase activity, but no correlation with
proliferative rates or cell senescence. All clones tested were capable of chondrogenic and osteogenic differentiation, though with large
variability in potency. In contrast, only 30% of the clones were adipogenic.
Conclusions. We report for the first time the co-existence, within the synovium, of progenitor cell subsets with distinct mesenchymal
differentiation potency. Our findings further emphasize the need for strategies to purify cell populations with the clinically desired tissue
formation potentials.
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Introduction
Increasing evidence supports the use of stem cells in the clinic.
A major concern is the large structural and clinical variability in
outcome, which limits standardization of stem cell-based therapies
and impedes comparison of clinical study outcomes [1, 2]. Such
variability is at least partly due to donor-related factors and the
inconsistency of stem cell preparations [3], as highlighted by
the report of contrasting results in clinical trials of cardiac cell
therapy [4].
Mesenchymal stem cells (MSCs) are clonogenic undifferen-
tiated cells capable of both self-renewal and differentiation into
lineages of mesenchymal tissues, including cartilage, bone, adipose
tissue and skeletal muscle. The ‘conventional’ MSCs are those
obtained from bone marrow (BM) [5–7]. However, MSCs have
been isolated from several other tissues, including the SM [8] and
SF [9], periosteum [10–12], skeletal muscle [13], adipose tissue [14]
and articular cartilage [15–17]. In view of their presence in many
easily accessible adult tissues and their ability to differentiate
into multiple lineages, MSCs are excellent candidates to be used
for skeletal tissue repair in regenerative medicine.
We reported the isolation and characterization of multipotent
MSCs from adult human SM (SM-MSCs) [8]. These cells were
derived from mixed unselected populations of adherent synovial
cells following in vitro expansion. SM-MSCs could be expanded
for up to at least 30 population doublings (PDs) with limited
senescence and maintenance of multilineage differentiation
capacity towards chondrogenesis, osteogenesis, adipogenesis and
skeletal myogenesis [8, 18–20].
The strategy for obtaining cell populations with predictable
tissue formation capacity would at least partly depend on the
presence of either multiple functionally distinct cell subsets or
more primitive stem cells capable of multilineage differentiation.
Human SM-MSCs, like the BM counterparts, appear heteroge-
neous in their growth and differentiation abilities [19, 21]. Mixed
cells are likely to produce an unpredictable biological activity
when used in the clinic. More functionally homogeneous cell
populations are desirable.
Multipotency of SM-MSCs was inherent to the single cell when
five clones were investigated as a proof-of-concept [8]. A more
systematic characterization of synovial progenitors at the single-
cell level is needed to investigate the possible co-existence of cell
subsets with distinct tissue formation capacity. Such characteriza-
tion will help devise novel strategies for purification of cell subsets
with a consistent and predictable biological activity.
In the present study, we analysed human synovial progenitor
cells at the single-cell level by studying clonal cell populations
derived by limiting dilution. We confirm wide variations in
growth and differentiation potentials between clones even
within the same donor sample and, for the first time, report the
co-existence, within the synovium, of progenitor cell subsets with
distinct mesenchymal differentiation potency.
Materials and methods
Harvest of synovium and isolation of cells
SM was collected aseptically, after informed consent, from the
knee joints of six human donors (Table 1). Three donors had a
history of OA and underwent total knee replacement, whereas the
remaining three donors had no history of knee joint disorders and
were referred to as normal. Ethical approval was obtained from
the local ethics committee (St Thomas’ Hospital Research Ethics
Committee).
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SM samples were rinsed twice with Hanks’ Balanced Salt
Solution (Invitrogen, Paisley, UK) supplemented with 2 antibio-
tic-antimycotic solution (100U/ml penicillin, 100g/ml strepto-
mycin and 0.25g/ml amphotericin B; Invitrogen), finely
minced and digested with 0.2% collagenase (Invitrogen) in
growth medium consisting of high-glucose DMEM (Lonza,
Slough, UK) supplemented with 10% fetal bovine serum (FBS;
Invitrogen) and antibiotics. Following overnight incubation at
378C, cells were collected by centrifugation, washed, further
digested for 5min at 378C with trypsin–ethylenediamine tetra-
acetate (EDTA) (0.25% trypsin, 1mM EDTA; Invitrogen),
washed again and filtered through a 70mm cell strainer
(Marathon Laboratory, London, UK). Red blood cells were
lysed. Cells were then counted using trypan blue (Sigma, Poole,
UK) to assess cell viability, and were either culture expanded
in growth medium or used to generate clonal populations by
limiting dilution.
Cell cloning and culture expansion
Cell cloning was performed by limiting dilution. Freshly isolated
or cultured cells were suspended in growth medium and plated at a
density of 0.3 viable cells per well in 96-well, flat-bottomed culture
plates. Four plates were used for each donor sample. At 30 days,
aggregates of more than 32 cells were scored as clones. Thirty-two
cells were chosen as this represents a population of cells derived
from more than five PDs of a single cell, thereby discounting
a transit-amplifying cell [22]. Up to 10 clones per donor sample
were selected. Cells were culture expanded in monolayer in
growth medium at 378C in a humidified atmosphere of
5% CO2. The medium was replaced every 3 days. Clonal cell
populations were subcultured upon reaching confluence. For
each clone, aliquots were cryopreserved.
Kinetics of growth
Cells were plated at a density of 3000 cells/cm2 in tissue culture
plates and were continuously passaged at the same density
whenever they reached sub-confluence. The number of viable
cells was determined at each passage using a haemocytometer.
The growth rate of each clone was expressed as number of
cumulative PDs during time. A graph was plotted against
duration in culture for a single cell to undergo 20 PDs.
Senescence-associated b-galactosidase staining
Senescence-associated -galactosidase (SA--gal) staining was
performed in chamber slides as described [23]. Cells were counter-
stained with Neutral Red (1% in water). Human Embryonic
Kidney (HEK) 293 cells and early passage (P4-P5) SM-MSCs
were used as a negative control. Late passage (P18) SM-MSCs
cells and senescent human dermal fibroblasts were used as a
positive control.
Osteogenesis assay
The in vitro osteogenesis assay was performed as described
earlier [8]. Each clone was plated in triplicate. Calcium content
was determined at 3 weeks of treatment with osteogenic medium
and normalized to protein content as described previously [19].
Total calcium was calculated from standard solutions and
expressed as micrograms per microgram of protein content.
Protein content was determined in parallel wells by the bicincho-
ninic acid protein assay (Sigma), using bovine serum albumin as
standard.
To stain calcium deposits, cells were rinsed twice with PBS,
fixed with 4% PFA and covered with alizarin red S solution
[2% aqueous solution (pH 4.2); Sigma) for 3min. Cultures were
then washed thoroughly with distilled water.
Chondrogenesis assay
The in vitro chondrogenesis assay was performed by combining
micromass culture and treatment with 10 ng/ml of TGF-1
(Biosource, Nivelles, Belgium) in a serum-free medium.
Micromass cultures were obtained by pipetting 20-l droplets of
cell suspension at a density of 2 107 viable cells/ml into indivi-
dual wells of 24-well plates. After cells were allowed to attach
without medium for 3 h, a serum-free medium consisting of
high-glucose DMEM supplemented with 50g/ml ascorbic acid,
ITSþ and 100 nM dexamethasone (all from Sigma) was added.
The day of plating in micromass culture was designated as
Day 0. Starting on Day 1, when the culture medium was changed,
TGF-1 was added to the culture medium every other day, at a
final concentration of 10 ng/ml. After 6 days, cultures were rinsed
twice with PBS, fixed with methanol for 30min at 208C, washed
and covered with Alcian blue at pH 0.2 [0.5% Alcian blue 8 GS
(Carl Roth, Karlsruhe, Germany) in 1N HCl]. After overnight
staining, cultures were washed extensively with distilled water.
For quantitative analyses, Alcian blue-stained cultures were
extracted with 200l of 6M guanidine HCl for 6 h at room tem-
perature. The absorbance of the extracted dye was measured at
630 nm by spectophotometry.
Adipogenesis assay
The in vitro adipogenesis assay was performed as described earlier
[24]. One hundred cells were plated in 60-cm2 cell culture dishes
and allowed to grow for 2 weeks. The medium of the treated
samples was then replaced with adipogenic induction (AI)
medium, consisting of growth medium supplemented with 1M
dexamethasone, 0.5mM 3-isobutyl-1-methyl-xanthine, 10g/ml
insulin and 100M indomethacin (all from Sigma). After 72 h,
the AI medium was replaced with adipogenic maintenance (AM)
medium, consisting of growth medium supplemented with
10g/ml insulin. After 24 h, the AM was discarded and cells
received two more treatments with alternating AI and AM. By
the end of the third treatment, the cells were maintained in AM for
a total of 21 days from the beginning of treatment. Cells were then
washed with PBS, fixed with 4% PFA, washed with water, rinsed
with 60% isopropanol, stained with Oil Red O solution [0.1%
Oil Red O (Sigma) in 60% isopropanol], rinsed again with 60%
isopropanol and washed extensively with water. The total number
of colonies was determined after counterstaining with crystal
violet (0.5% in methanol).
Telomere length assay
Genomic DNA was extracted from clonal cell monolayers using
one-step lysis and DNA exclusion columns (Nexttec, MP Sciences,
Wellingborough, UK) and the amount quantified fluorescently
using PicoGreen (Molecular Probes, Eugene, Oregon, USA).
Telomere lengths were determined semi-quantitatively by
Southern blotting using TeloTAGGG telomere length assay,
according to the recommendations of the manufacturer
(Roche, Lewes, UK). Mean telomere lengths were determined
by densitometric scanning of exposed X-ray film.
TABLE 1. Synovial tissue specimens used in the study
Donor Age, years Sex Clinical history No. of clones Passage
A 55 M N 7 Fresh
B 74 F OA 6 P6
C 58 F N 9 P7
D 73 F OA 8 Fresh
E 90 F N 10 Fresh
F 74 F OA 10 P1
M: male; F: female; N: normal (donors had no history of knee joint disorders and did not have
active infections or tumours); P: number of passage of parental cells, from which clones were
derived by limiting dilution.
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Telomerase activity
Comparative analysis of telomerase activity was performed
using a real-time quantitative telomerase repeat amplification
procedure (RTQ-TRAP) as described [25]. Cell extracts
were obtained by adding 200l of lysis buffer per 1 106 cells
(lysis buffer; 10mM Tris pH 8.3, 1.5mM MgCl2, 1mM
ethylene glycol tetraacetic acid (EGTA), 10% glycerol, 0.5%
3[(3-Cholamidopropyl)dimethylammonio]-propanesulfonic acid
(CHAPS) buffer, 1mM phenylmethylsulphonyl fluoride (PMSF),
5mM -mercaptoethanol and 200 U RNAsin). Each RTQ-
TRAP reaction was composed of 1SYBR Green Mastermix
(Eurogentec, Seraing, Belgium), 10mM EGTA, 0.2g T4 gene
protein, 0.3M primers TS (50-AATCCGTCGAGCAGAGT
T-30) and ACX (50-GCGCGG[CTT ACC]3CTAACC-30) and
25 103 cell extract in a final volume of 25l. The reaction
mixture was incubated at 258C for 20min to allow TS primer
extension by telomerase, heated to 958C for 10min to activate
Taq polymerase, followed by 40 cycles at 958C for 20 s, 508C
for 30 s and 728C for 90 s. Telomerase activity in cell samples
was calculated based on the threshold cycle (CT). All samples
were run in triplicate, and lysis buffer was used as a negative
control. Immortal human leukaemia cell line 60 (HL60) was
used as a positive control for telomerase activity. HL60 cell
extracts were serially diluted and assayed by RTQ-TRAP to
generate a standard curve that was used to derive telomerase
activity based on the HL60 cell equivalent units.
Phenotyping of clonal cell populations using three-colour
flow cytometry
Culture-expanded clonal cell populations were used for flow
cytometry at 105 cells/test. Phycoerythrin (PE)-conjugated anti-
bodies were: CD166 and CD73 (Pharmingen, Oxford, UK),
CD105 and CD90 (Serotec, Oxford, UK) and SSEA-4 (R&D
Systems, Abingdon, UK). FITC-conjugated antibodies were:
CD45 (Dako, High Wycombe, UK), CD13 and CD31 (Serotec),
CD81 (Pharmingen) and CD271 (Miltenyi Biotec, Bisley, UK).
Isotype-specific negative control antibodies were purchased from
Serotec. Data were acquired using BD FACScan and dead cells
were gated out based on propidium iodide exclusion (Sigma).
All flow cytometry data were analysed with WinMDI v8
(Scripps Research Institute, La Jolla, California, USA).
Statistical analysis
Data are presented as mean S.D. apart from flow cytometry
data, which are shown as median (range) of percentage positive
cells. Each assessment was performed on two or three cultures
per clonal cell population. Pearson’s product moment correlation
coefficient r was calculated in order to assess the linear associa-
tions between variables. Means were compared using one- and
two-factorial analysis of variance (ANOVA) as a priori test and
Fisher’s least significant difference as a posteriori test. For all
correlations and comparisons of means, P< 0.05 was considered
significant.
Results
Growth potential of clonal populations
We first analysed the proliferative capacity of single cell-derived
clonal populations. Clonal populations were derived by limiting
dilution in 96-well plates. Four plates were set up for each of the
six individual donors. A total of 50 clones were randomly selected
(see Table 1 for details). Out of these 50 clones, three clones
stopped growing after 17–18 PDs, whereas the remaining
47 clones were able to grow beyond 20 PDs. More in detail,
seven clones reached 25 PDs, 25 clones grew beyond 30–35 PDs,
11 clones exceeded 40 PDs and four clones grew beyond 50 PDs.
The proliferative capacities of the individual clones were
assessed according to the time taken by a single cell to undergo
20 PDs. A wide variation in the proliferation rates was observed
between the clones, across the donors and within the same donor.
The time taken to reach 20 PDs ranged from 44 to 130 days
(Fig. 1). The clones obtained from donor sample B were growing
faster and displayed less variation in their proliferative capacities
than the clones of the other samples tested (P< 0.05). The clones
of donor A were significantly faster than the clones of donors
C and E (P< 0.05).
Phenotype
To evaluate the phenotype of the expanded clonal cells, we
performed fluorescence-activated cell sorting analysis, testing
five representative clones (A2, A8, D1, D3 and E10) for the
expression of a marker set associated with multipotent MSCs
[5, 10, 19] (Fig. 2). All clones tested were negative for the haemato-
poietic cell marker CD45 and the endothelial cell marker CD31,
both known to be not expressed by MSCs [5]. CD271/LNGFR
was also undetectable, as reported with culture-expanded non-
clonal MSC populations [19, 26]. Clones displayed variable
expression of the MSC-positive markers CD13, CD105, CD73,
CD166, SSEA4, CD81 and CD90. These data indicate that
the clonal cells tested display a phenotype compatible with
culture-expanded MSCs.
Replicative senescence, telomere length and telomerase
activity
MSCs are somatic cells that display a long-term self-renewal
capacity in vitro that is dependent upon factors such as replicative
senescence, telomere length and telomerase activity. We first
investigated the occurrence of cell senescence by assessing,
during clonal culture expansion, the SA--gal, an assay that
detects the presence of the -gal enzyme expressed by senescent
cells [23]. For this assay, we selected clones of donor A, which
were heterogeneous in their proliferative capacity, and clones of
donor B, which instead displayed similar and overlapping growth
curves (Fig. 1 and data not shown). After 18 PDs, cells were
mostly negative and had a fibroblast-like morphology, whereas
after 30–35 PDs cells stained intensely for SA--gal and were
morphologically flat and bigger in size (Fig. 3A), features consis-
tent with the senescent phenotype. An increase in the proportion
of SA--galþ senescent cells during time in culture was observed in
most of the clonal populations (Fig. 3B), although with variability
across the clones tested. For Donor A, the increase was significant
at 25 and 35 PDs compared with 18 PDs (P< 0.05), whereas
for Donor B it was significant at 35 PDs compared with 18 and
25 PDs (P< 0.05).
We then measured telomere lengths and telomerase activity
in 11 clonal populations after a number of PDs ranging between
23 and 49. Despite the extensive expansion in culture, all clones
displayed relatively long telomeres, ranging from 5.2 (clone C6) to
10.9 kb (clone A5—Fig. 4A). Telomerase activity, determined as
the equivalence of each clone to HL60 cell line, was between
0.0734 (B3) and 1.024 (E10). Mean telomere length displayed
positive linear trend with telomerase activity (r¼ 0.63, P< 0.05;
Fig. 4B). Neither telomere length nor telomerase activity corre-
lated with replicative senescence, cumulative number of PDs or
PD duration at the time of their measurements.
Differentiation potential of clonal populations
A total of 21 clones were tested for their ability to differentiate
towards mesenchymal lineages using well-established in vitro
assays (Fig. 5). These assays were performed after a cumulative
number of PDs ranging between 22 and 28, with the exception of
clone A2, tested after 41 PDs, and clones A8, A9 and B2, which
were assessed after 48 PDs. There was considerable variation in
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FIG. 2. Surface marker phenotype of synovial clonal cells following culture expan-
sion. Results from a representative clone (A8) are shown. For each marker tested,
values are shown as median (range) of the percentage of positive cells for the five
clones tested. Solid histograms show marker expression; open histograms show
negative isotype controls. Horizontal line shows positive cells.
FIG. 1. Proliferation rates of individual clones to undergo 20 PDs. Each bar
represents the time needed for each clone to reach 20 PDs. Striped bars indicate
the clones that were tested for cell differentiation assays. The clones that were
further analysed for telomere lengths and telomerase activity (T) and phenotype by
flow cytometry (FACS) are also labelled. On the y-axis, capital letters and numbers
indicate donors and corresponding clones, respectively.
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the extent of differentiation between the clonal populations tested,
across donors and within the same donor.
All clones were chondrogenic as determined by alcian blue
staining of TGF-1-treated micromasses, with absorbance ran-
ging from 0.15 to 0.44. One clone (D1) was highly chondrogenic
with an absorbance of 0.76. Untreated clones were negative
(Fig. 5A and B).
All clones responded to osteogenic treatment in monolayers
as assessed by Alizarin red staining for calcium (Fig. 5C). For
quantitation, we measured calcium deposition, which we recently
reported to be significantly correlated, under specific conditions,
with the amount of ectopic bone formation in vivo following
subcutaneous transplantation of human MSC-seeded scaffolds
in nude mice [19]. Under our conditions, untreated clones did
not show any calcium deposition (Fig. 5C). In contrast, treated
clones responded with deposition of calcium ranging from
0.6 to 4.1g per microgram of proteins (Fig. 5D).
Adipogenic differentiation was assessed by Oil Red O staining.
While all clones gave rise to colonies as assessed by staining with
crystal violet, only seven out of the 21 clones tested generated
colonies of adipocytes, which stained with Oil Red O (Fig. 5E).
The rate of Oil Red O-positive colonies varied between 1.6 (B6)
and 38% (E4—Fig. 5F).
Under our experimental conditions, the differentiation
potentials of the tested clonal populations did not correlate with
cumulative PDs, markers, replicative senescence, telomere length
or telomerase activity. In addition, no correlation was observed
between chondrogenic, osteogenic and adipogenic potentials of
individual clonal populations.
Discussion
Several studies indicate the therapeutic utility of MSCs in
humans [27–32]. However, inconsistency of MSC preparations
limits standardization. To develop standard protocols for a cell
transplant with the prospect to be used routinely in the clinic, a
requirement is the obtainment of a sufficient number of well-
defined MSCs, which should possess fundamental characteristics
such as proliferative capacity as well as known potency with
related ability to deposit the required matrix proteins. We pre-
viously reported that human SM-MSCs possess high self-renewal
capacity and a multipotency that is inherent to the single cell
when using a limited number of clones as a proof-of-concept [8].
Here, we characterized synovial mesenchymal cells more
systematically at the single-cell level using clonal populations
obtained by limiting dilution, with a goal of discerning multi-
potent stem cell pools from progenitor cell populations with
more restricted potency. Such information is clinically relevant
for the standardization of tissue engineering applications employ-
ing human MSCs.
It is known from previous studies that single cell-derived
clonal MSC populations become heterogeneous during culture
expansion [19, 33, 34]. The phenotypic heterogeneity within each
clonal population may be due to the different status of the
individual cells of the single cell progeny (e.g. different phases of
cell cycle, symmetric or asymmetric cell division and different
stages of differentiation). Nonetheless, we opted to study, in
depth, clonal populations as cells within a single cell-cloned popu-
lation are genetically and perhaps epigenetically homogeneous,
FIG. 3. SA--gal activity. (A) SA--gal staining of a fast-growing clone (A5) and a slow-growing clone (A6) throughout culture expansion. (a) and (b) show clone A5 after
18 PDs (54 days) and 35 PDs (144 days), respectively; (c) and (d) show clone A6 after 19 PDs (54 days) and 30 PDs (171 days), respectively. Senescent cells appear blue.
Counterstaining is with neutral red. Scale bar¼50m. (B) Percentage of SA--galþ (senescent) cells in clones selected from Donors A and B after 18, 25 and 35 PDs.
Results indicate a trend in progressive increase in replicative senescence paralleling the increase in PDs.
FIG. 4. Telomere length and telomerase activity. (A) Southern blotting for telomeres. Eleven culture-expanded clonal populations (as indicated) were analysed by Southern
blotting for the length of their telomeres. Note the apparent gaps in the DNA streaks, which confirm the purity of single cell-derived clonal populations. The mean telomere
length of each clone is indicated in kilobase pairs. The U937 cell line was used as a positive control (HMW: high-molecular weight; mean telomere length 10.2 kb), and the
HL-60 cell line was used as a negative control (LMW: low molecular weight; mean telomere length 3.9 kb). (B) Plot of mean telomere length (kb) vs telomerase activity,
expressed as arbitrary units (ratio of the clonal cell equivalents divided by the HL60 cell equivalent units) (r¼ 0.63, P<0.05).
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which would explain why clonal cells maintain in culture a certain
degree of functional consistency [19].
In keeping with our previous study [19], wide variations in the
proliferation rates were observed between clones, even within
clones from the same donor sample. This suggests that plastic
adherent non-clonal synovial MSCs do not consist of a uniform
population of stem cells. It is worth mentioning that not all of
the clones were culture-expandable under our conditions, with
three of the 50 clones tested unable to grow beyond 20 PDs.
One factor possibly accounting for the growth heterogeneity of
clonal populations is cell senescence, a common phenomenon
occurring to various degrees in somatic cells during in vitro
expansion. As expected, and in keeping with our previous work
with non-clonal SM-MSCs [8], we observed a general increase in
SA--Galþ cells with increasing PDs. Highly expressing SA--gal
cells were more enlarged and flatter in morphology, compatible
with the senescent phenotype. Interestingly, in some clones
the percentage of SA--galþ cells decreased to then increase
again over accumulating PDs, rather than increase continuously.
This could be due to variability in the assay, or re-activation of
telomerase activity [35], or emergence within the clonal progeny of
cell subsets having clonogenic advantage due, for instance,
to somatic mutations [36]. In addition, there is evidence that
replicative senescence may be reversible as some senescent cells
can, under specific conditions, recover from growth arrest,
re-enter cell cycle and replicate their DNA [37, 38].
Although the phenomenon of senescence is not fully under-
stood, it is believed that rather than being the result of cell
ageing, it is more likely to be a protective mechanism, not neces-
sarily irreversible, activated by normal cells in response to various
types of stress such as carcinogenesis [39]. Indeed, SM-MSCs do
not form tumours when injected into mice [18], a property that
would favour their use in cell-based therapies.
Telomere maintenance by telomerase is thought to be necessary
for a high number of cell divisions [40]. We observed a positive
linear trend between telomerase activity and mean telomere
length, supporting the accuracy of our experiments. However,
under our experimental conditions, in vitro growth rate and cell
senescence, known to be related to telomere shortening [41], did
not show any correlation with mean telomere length or telomerase
activity, and clonal populations were able to grow when their
mean telomere lengths were 5–6 kb. A clear correlation was
reported between telomere length and proliferative capacity of
human BM non-clonal MSCs, with MSC populations stopping
dividing at 10 kb [42]. These apparent discrepancies could be
due to donor-related factors, culture conditions, use of clonal vs
non-clonal MSC populations or different MSC tissue sources.
Together with the high threshold telomere length reported
FIG. 5. In vitro mesenchymal differentiation assays. Twenty-one culture-expanded clonal populations were subjected to differentiation assays. (A and B) Chondrogenic
differentiation. Cells were plated in micromass culture and were either treated (þ) or not treated (–) with TGF-1 for 6 days. (A) Representative picture of Alcian blue stained
micromasses (in duplicate). (B) Stained micromasses were extracted with 6 M guanidine HCl, and the absorbance of the extracted dye was measured at 630 nm. Data are
shown as the mean S.D. of duplicates. (C and D) Osteogenic differentiation. Clonal cell populations in monolayers were either treated (þ) or not treated (–) with osteogenic
medium for 3 weeks. (C) Representative picture of Alizarin red stained cells (in duplicate). (D) Quantitation of calcium deposition (expressed as micrograms of calcium per
microgram of protein content, determined in parallel wells). Data are shown as mean S.D. of triplicates. (E and F) Adipogenic differentiation. (E) Representative picture
of Oil Red O-stained cells upon adipogenic treatment. (F) Percentage of Oil Red O-positive colonies per each clone.
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in BM-MSCs [42], our findings suggest that mechanisms
independent of telomere shortening [41], such as accumulated
damage, contribute to cell senescence and growth arrest in
cultured MSCs.
Variations in the growth potential of clonal populations could
be due to the co-existence of multiple cell types selected by plastic
adherence and grown under our culture conditions. Indeed, the
identity of synovial MSCs in relation to other stromal cells such
as fibroblasts is not known. Both synovial MSCs and fibroblasts
are derived following enzymatic digestion of synovial tissue and
culture expansion of the plastic-adherent fibroblast-like cells.
Culture-expanded clonal populations in our study displayed a
phenotype compatible with conventional MSCs and expressed
SSEA-4, which was not detected in 3T3 fibroblasts [43].
However, markers alone would not be sufficient to rule out the
presence of fibroblasts or their progeny in our clones as culture
conditions are known to affect cell phenotype. In addition,
primary fibroblasts derived from various human tissues including
lung and skin were reported to contain cells that were able to
differentiate into osteoblasts, chondrocytes and adipocytes [44].
Investigations are therefore needed to elucidate the relationship
between MSCs and fibroblasts.
We previously reported that SM-MSCs are multipotential
with a single cell-inherent ability to differentiate down the chon-
drogenic, osteogenic and adipogenic pathways in vitro, when using
a few clones as a proof-of-concept [8]. In the present study, we
analysed 21 clones from six donors and observed that all clonal
populations were chondro-osteogenic, whereas seven of the
21 clones were also adipogenic under our experimental conditions.
When the same in vitro cell differentiation assays were performed
using parental cells (i.e. mixed non-clonal cell populations),
SM-MSCs were tripotential (data not shown). Altogether, our
findings suggest the co-existence in synovium of progenitor cell
subsets with distinct differentiation abilities. It has to be noted,
however, that in order to characterize single cell clonal popula-
tions high numbers of cells are required to perform all the tests
described in this study. The extensive culture expansion may have
caused, in some clonal populations, loss of adipogenic potential
that was originally present in the cells, as has been suggested for
BM-MSCs [45]. It is thus possible that some synovial clones
retained their multipotentiality through a high number of PDs,
whereas other clones lost the ability to form adipocytes whilst
retaining chondro-osteogenic capacity.
To our knowledge, this is the first study to report the existence
of single cell-derived clonal populations in the synovium that are
chondro-osteogenic but unable to differentiate into adipocytes.
As reported with BM-MSCs [45], we did not observe clones
with a differentiation potential restricted to the osteo-adipogenic
or to the chondro-adipogenic phenotype.
In a previous study with BM-derived clonal MSC populations
[46], wide variations were observed in clonal cell replication, which
were directly related to the clonal differentiation potentials. In our
study, we did not observe any correlation between any feature
of growth rate and the clonal differentiation potential. All these
findings indicate the need of developing protocols for purification
of cells that display functional homogeneity and predictable
biological behaviour for cell-based therapy. In the present study,
as well as in our previous work [19], clones expressed the putative
MSC markers, but the markers tested did not correlate with the
differentiation potential. This would emphasize the need to search
for novel cell surface markers of MSCs that would be linked
to specific biological behaviours and could therefore be used as
quality controls in the cell manufacturing process.
The generation of consistent MSC-based therapeutic protocols
is a pre-requisite to translating stem cell technologies into routine
clinical application. We do not advocate the use of clonal popula-
tions in the clinic, as this would be impractical and costly.
However, studies of clonal populations will help in the identifica-
tion of marker sets for prospective purification of mesenchymal
stem/progenitor cell subpopulations, functionally homogeneous
in their clinically preferred differentiation capacities. Such
purification will increase the consistency of cell preparations for
clinical use.
Rheumatology key messages
 This study reveals heterogeneity of synovial mesenchymal
progenitor/stem cells and co-existence of cell subsets with distinct
tissue formation abilities.
 This emphasizes the need of purification of progenitor cells
displaying functional homogeneity for consistent cell therapy.
Acknowledgements
C.D.B. is a Fellow of the Medical Research Council, UK and
F.D’A. is a Fellow of the Arthritis Research Campaign, UK.
Funding: This study was supported by MRC grant G108/620.
Disclosure statement: The authors have declared no conflicts of
interest.
References
1 De Bari C, Dell’Accio F. Mesenchymal stem cells in rheumatology: a regenerative
approach to joint repair. Clin Sci 2007;113:339–48.
2 De Bari C, Dell’Accio F. Cell therapy: a challenge in modern medicine. Biomed Mater
Eng 2008;18(Suppl. 1):S11–17.
3 De Bari C, Pitzalis C, Dell’Accio F. Reparative medicine: from tissue engineering to
joint surface regeneration. Regen Med 2006;1:59–69.
4 Rosenzweig A. Cardiac cell therapy—mixed results from mixed cells. N Engl J Med
2006;355:1274–7.
5 Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human
mesenchymal stem cells. Science 1999;284:143–7.
6 Caplan AI, Bruder SP. Mesenchymal stem cells: building blocks for molecular
medicine in the 21st century. Trends Mol Med 2001;7:259–64.
7 Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues.
Science 1997;276:71–4.
8 De Bari C, Dell’Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem
cells from adult human synovial membrane. Arthritis Rheum 2001;44:1928–42.
9 Jones EA, English A, Henshaw K et al. Enumeration and phenotypic characterization
of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and
degenerative arthritis. Arthritis Rheum 2004;50:817–27.
10 De Bari C, Dell’Accio F, Vanlauwe J et al. Mesenchymal multipotency of adult human
periosteal cells demonstrated by single-cell lineage analysis. Arthritis Rheum
2006;54:1209–21.
11 Nakahara H, Bruder SP, Haynesworth SE et al. Bone and cartilage formation in
diffusion chambers by subcultured cells derived from the periosteum. Bone
1990;11:181–8.
12 De Bari C, Dell’Accio F, Luyten FP. Human periosteum-derived cells maintain
phenotypic stability and chondrogenic potential throughout expansion regardless of
donor age. Arthritis Rheum 2001;44:85–95.
13 Asakura A, Komaki M, Rudnicki M. Muscle satellite cells are multipotential stem cells
that exhibit myogenic, osteogenic, and adipogenic differentiation. Differentiation
2001;68:245–53.
14 Zuk PA, Zhu M, Mizuno H et al. Multilineage cells from human adipose tissue:
implications for cell-based therapies. Tissue Eng 2001;7:211–28.
15 Dell’Accio F, De Bari C, Luyten FP. Microenvironment and phenotypic stability
specify tissue formation by human articular cartilage-derived cells in vivo. Exp Cell
Res 2003;287:16–27.
16 Alsalameh S, Amin R, Gemba T, Lotz M. Identification of mesenchymal progenitor
cells in normal and osteoarthritic human articular cartilage. Arthritis Rheum
2004;50:1522–32.
17 Dowthwaite GP, Bishop JC, Redman SN et al. The surface of articular cartilage
contains a progenitor cell population. J Cell Sci 2004;117:889–97.
18 De Bari C, Dell’Accio F, Vandenabeele F, Vermeesch JR, Raymackers JM,
Luyten FP. Skeletal muscle repair by adult human mesenchymal stem cells from
synovial membrane. J Cell Biol 2003;160:909–18.
19 De Bari C, Dell’Accio F, Karystinou A et al. A biomarker-based mathematical model
to predict bone-forming potency of human synovial and periosteal mesenchymal
stem cells. Arthritis Rheum 2008;58:240–50.
20 De Bari C, Dell’Accio F, Luyten FP. Failure of in vitro-differentiated mesenchymal
stem cells from the synovial membrane to form ectopic stable cartilage in vivo.
Arthritis Rheum 2004;50:142–50.
21 Ho AD, Wagner W, Franke W. Heterogeneity of mesenchymal stromal cell prepara-
tions. Cytotherapy 2008;10:320–30.
Progenitor cell subsets in synovium 1063
22 Jones PH, Watt FM. Separation of human epidermal stem cells from transit amplify-
ing cells on the basis of differences in integrin function and expression. Cell
1993;73:713–24.
23 Dimri GP, Lee X, Basile G et al. A biomarker that identifies senescent human cells in
culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995;92:9363–7.
24 Sakaguchi Y, Sekiya I, Yagishita K, Muneta T. Comparison of human stem cells
derived from various mesenchymal tissues: superiority of synovium as a cell
source. Arthritis Rheum 2005;52:2521–9.
25 Hou M, Xu D, Bjorkholm M, Gruber A. Real-time quantitative telomeric repeat
amplification protocol assay for the detection of telomerase activity. Clin Chem
2001;47:519–24.
26 Jones EA, Kinsey SE, English A et al. Isolation and characterization of bone marrow
multipotential mesenchymal progenitor cells. Arthritis Rheum 2002;46:3349–60.
27 Quarto R, Mastrogiacomo M, Cancedda R et al. Repair of large bone defects with the
use of autologous bone marrow stromal cells. N Engl J Med 2001;344:385–6.
28 Vacanti CA, Bonassar LJ, Vacanti MP, Shufflebarger J. Replacement of an avulsed
phalanx with tissue-engineered bone. N Engl J Med 2001;344:1511–14.
29 Warnke PH, Springer IN, Wiltfang J et al. Growth and transplantation of a custom
vascularised bone graft in a man. Lancet 2004;364:766–70.
30 Wakitani S, Imoto K, Yamamoto T, Saito M, Murata N, Yoneda M. Human autologous
culture expanded bone marrow mesenchymal cell transplantation for repair of
cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage 2002;10:199–206.
31 Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived
mesenchymal cells engraft and stimulate growth in children with osteogenesis
imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA
2002;99:8932–7.
32 Horwitz EM, Prockop DJ, Fitzpatrick LA et al. Transplantability and therapeutic
effects of bone marrow-derived mesenchymal cells in children with osteogenesis
imperfecta. Nat Med 1999;5:309–13.
33 Colter DC, Class R, DiGirolamo CM, Prockop DJ. Rapid expansion of recycling stem
cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad
Sci USA 2000;97:3213–18.
34 Colter DC, Sekiya I, Prockop DJ. Identification of a subpopulation of rapidly self-
renewing and multipotential adult stem cells in colonies of human marrow stromal
cells. Proc Natl Acad Sci USA 2001;98:7841–5.
35 Bianchi A, Shore D. How telomerase reaches its end: mechanism of telomerase
regulation by the telomeric complex. Mol Cell 2008;31:153–65.
36 Yamanishi Y, Boyle DL, Green DR et al. p53 tumor suppressor gene mutations in
fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in
rheumatoid arthritis. Arthritis Res Ther 2005;7:R12–18.
37 Blank M, Shiloh Y. Programs for cell death: apoptosis is only one way to go. Cell
Cycle 2007;6:686–95.
38 Brookes S, Rowe J, Ruas M et al. INK4a-deficient human diploid fibroblasts are
resistant to RAS-induced senescence. EMBO J 2002;21:2936–45.
39 Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senes-
cence. Int J Biochem Cell Biol 2005;37:961–76.
40 Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev 2008;88:557–79.
41 Herbig U, Sedivy JM. Regulation of growth arrest in senescence: telomere damage is
not the end of the story. Mech Ageing Dev 2006;127:16–24.
42 Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of
telomere length reveals rapid aging of human marrow stromal cells following in vitro
expansion. Stem Cells 2004;22:675–82.
43 Gang EJ, Bosnakovski D, Figueiredo CA, Visser JW, Perlingeiro RC. SSEA-4
identifies mesenchymal stem cells from bone marrow. Blood 2007;109:
1743–51.
44 Sudo K, Kanno M, Miharada K et al. Mesenchymal progenitors able to differentiate
into osteogenic, chondrogenic, and/or adipogenic cells in vitro are present in most
primary fibroblast-like cell populations. Stem Cells 2007;25:1610–17.
45 Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human
bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci
2000;113:1161–6.
46 Mareddy S, Crawford R, Brooke G, Xiao Y. Clonal isolation and characterization
of bone marrow stromal cells from patients with osteoarthritis. Tissue Eng
2007;13:819–29.
1064 Alexandra Karystinou et al.
